FDA Names Spectramax Light Therapy ‘Breakthrough Device’ for Parkinson’s

FDA Names Spectramax Light Therapy ‘Breakthrough Device’ for Parkinson’s
The United States Food and Drug Administration (FDA) has granted breakthrough device designation to PhotoPharmics‘s light-based, at-home device as an add-on therapy for Parkinson’s disease. This designation is given to medical devices with the potential to offer more effective treatment for life-threatening or debilitating diseases. It grants the company access to experts at the FDA during development, and paves the way ... read more
Source: Parkinson’s News TodayPublished on 2020-05-04By Marisa Wexler